Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Time For Big Pharma To Take Back Orphan Drugs

Executive Summary

The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.

Advertisement

Related Content

Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Speaking Up For Orphan Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register